Open Access

New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)

  • Authors:
    • Krupa R. Bhaliya
    • Muneera Anwer
    • Alan Munn
    • Ming Q. Wei
  • View Affiliations

  • Published online on: October 31, 2024     https://doi.org/10.3892/mco.2024.2799
  • Article Number: 4
  • Copyright: © Bhaliya et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Therapeutic approaches that increase the efficacy and safety of cancer treatments and improve disease outcomes have been developed worldwide. Immunotherapy uses the body's immune system to inhibit cancerous growth in tissues and organs. Various approaches have been developed to effectively control and inhibit cancerous growth, including checkpoint inhibitors, T‑cell transfer therapy, monoclonal antibodies, vaccines and immunomodulators. Toll‑like receptors (TLRs) target malignant cells by equipping the immune response. In addition, TLR agonists serve a key role in promoting the innate immune system and initiating antigen‑specific T‑cell responses. Notably, TLRs and TLR agonists have been utilized as monotherapies or in combination for the treatment of cancer. The present study aimed to review the use of R848 and R837 as TLR agonists, and outline their use as key immunomodulators in cancer therapy.
View Figures
View References

Related Articles

Journal Cover

January-2025
Volume 22 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bhaliya KR, Anwer M, Munn A and Wei MQ: New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review). Mol Clin Oncol 22: 4, 2025.
APA
Bhaliya, K.R., Anwer, M., Munn, A., & Wei, M.Q. (2025). New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review). Molecular and Clinical Oncology, 22, 4. https://doi.org/10.3892/mco.2024.2799
MLA
Bhaliya, K. R., Anwer, M., Munn, A., Wei, M. Q."New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)". Molecular and Clinical Oncology 22.1 (2025): 4.
Chicago
Bhaliya, K. R., Anwer, M., Munn, A., Wei, M. Q."New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review)". Molecular and Clinical Oncology 22, no. 1 (2025): 4. https://doi.org/10.3892/mco.2024.2799